Fierce Pharma

DECEMBER 1, 2023

Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition law, according to a release from the country's government.

Competition 233

Competition Government Pharmaceutical 233

MedCity News

DECEMBER 1, 2023

At RSNA 2023, Nvidia launched new set of cloud-based APIs designed to speed up the creation and deployment of specialized AI models in the medical imaging field. The new offering is a cloud-native extension to Nvidia’s Monai framework, which is its open-source framework for medical imaging AI.

Medical 129

Medical Specialization Healthcare Healthcare 129

Fierce Pharma

DECEMBER 1, 2023

After a hard-fought battle for FDA approval, AstraZeneca has hit another setback on its quest to turn its potassium-reduction drug Lokelma into a blockbuster. | AstraZeneca has put the kibosh on two late-stage Lokelma trials testing the hyperkalemia drug in patients with heart and kidney diseases. The studies were called off due to “substantially increased enrollment times and low event rates,” AZ said Friday.

Pharma 222

Pharma FDA Patients 222

MedCity News

DECEMBER 1, 2023

The Patient-Centered Outcomes Research Institute announced that it is funding four studies focused on reducing maternal health inequities. The studies all leverage partnerships with community organizations.

Patients 121

Patients 121

Advertisement

Distribution

Fierce Pharma

DECEMBER 1, 2023

Texas attorney general Ken Paxton is going after Pfizer—again. | Texas attorney general Ken Paxton is going after Pfizer—again. Less than two weeks after documents were unsealed showing that Texas has accused Pfizer and manufacturer Tris Pharma of providing a compromised ADHD medicine to the state, Paxton has sued Pfizer for “unlawfully misrepresenting the effectiveness” of the company’s COVID-19 vaccine.

Manufacturing 213

Manufacturing Medicine Pharma 213

PharmExec

DECEMBER 1, 2023

Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.

115

115

Pharmaceutical Commerce

DECEMBER 1, 2023

In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.

FDA 110

FDA Patients 110

MedCity News

DECEMBER 1, 2023

We should strive for a future where patients have easy and affordable access to medications, supported on their journey by trusted pharmacy professionals who are an integral part of their care team.

Patients 105

Patients Medical 105

European Pharmaceutical Review

DECEMBER 1, 2023

AbbVie has agreed to acquire ImmunoGen and its first-in-class antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx), for a total of approximately $10.1 billion. The antibody-drug conjugate is the first to be approved for platinum-resistant ovarian cancer (PROC) and show meaningful survival benefit for this form of the disease. As a folate receptor alpha (FRα) with a maytansinoid payload DM4, a potent tubulin inhibitor, the biologic medicine offers expansion opportunities in e

Food and Drug Administration 107

Food and Drug Administration FDA Marketing Food 107

MedCity News

DECEMBER 1, 2023

Laying AI functions on top of already outdated systems or relying on separate solutions that do not play into the unified stack system––especially given the volume of data, delicate privacy issues and the need for constant updates––does not optimally contribute to the advancement of radiology.

Medical 105

Medical 105

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Referral MD

DECEMBER 1, 2023

Managing dental referrals can be tedious, involving phone calls, emails, and endless paperwork. Dental referral software offers a comprehensive solution by digitizing the entire process. You can send and receive referrals, track their progress, and easily communicate with other dental practices with just a few clicks. Say goodbye to lost referrals and hello to a more organized and efficient workflow!

Marketing 94

Marketing Patients Engineering Media 94

MedCity News

DECEMBER 1, 2023

Practices should take a fresh look at their coding quality, which can help reduce denials, payer takebacks, and cash flow issues. Implementing intensive coding training, CAC technology, and internal audit and review programs can help. However, for practices that lack the resources to make such investments, outsourcing may be a better approach.

Training 104

Training Physicians Medical 104

European Pharmaceutical Review

DECEMBER 1, 2023

Since its introduction in 1980, capillary electrophoresis (CE) has been one of the most powerful techniques applicable as a choice method in the biopharmaceutical industry for the characterisation and quality control (QC) testing of biomolecules such as proteins, peptides as well as monoclonal antibodies (mAbs) and high molecular weight polysaccharides. 1 In addition to the intrinsic advantages of CE, such as high separation efficiency, high resolution, low sample volume requirements, short sepa

Pharmaceutical 90

Pharmaceutical 90

MedCity News

DECEMBER 1, 2023

As a heart transplant recipient less than three years out from quadruple organ failure, and a father of two young children, I’m not just hoping that modernization will save and extend more lives. I’m counting on it.

104

104

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Pharmaceutical Technology

DECEMBER 1, 2023

Hot on the heels of the designation, Orchard Therapeutics is pressing ahead with a multi-centre trial for the candidate with a start date in December.

FDA 98

FDA 98

MedCity News

DECEMBER 1, 2023

It is only by supporting the public health workers, and making their jobs more appealing that health agencies can strengthen the workforce to prevent and respond to future public health threats.

Training 90

Training 90

Eversana Intouch

DECEMBER 1, 2023

Recently, Ad Forum published an article highlighting five campaigns it found to be “ Raising the Bar for Health Equity in Advertising.” One was our ongoing work with The Chrysalis Initiative, a nonprofit working to eliminate racial disparities in breast cancer treatment. This alliance dates back to 2021, but in 2023, as Fierce Pharma put it, we “ roared back from rejection to craft a Cannes-winning campaign hospitals couldn’t ignore.

Pharma 87

Pharma Management Leads Marketing 87

European Pharmaceutical Review

DECEMBER 1, 2023

A new report by the Committee of Experts on minimising the public health risks posed by falsified medical products and related crimes (CD-P-PH/CMED) shares insight on how authorities perceive and address the falsification of medical devices. The report details findings from survey completed by 21 of the 46 Council of Europe member states on counterfeit medical devices.

Medical 87

Medical Pharmaceutical 87

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Pharmaceutical Technology

DECEMBER 1, 2023

The SMC and NICE have recommended the use of AstraZeneca’s durvalumab to treat advanced biliary tract cancers in England and Scotland.

97

97

European Pharmaceutical Review

DECEMBER 1, 2023

During CPHI Barcelona, EPR Editor Caroline Peachey asked Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, at Thermo Fisher Scientific about the dynamic landscape of pharmaceutical drug development. Dr Kane leads a team of subject matter experts at Thermo Fisher, covering drug products in both sterile injectable dosage and oral solid dosage forms.

Food and Drug Administration 85

Food and Drug Administration Manufacturing Pharma Patients 85

PharmaTimes

DECEMBER 1, 2023

Every year, over 44,000 men are diagnosed with prostate cancer in England - News - PharmaTimes

Patients 112

Patients 112

pharmaphorum

DECEMBER 1, 2023

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD and DIALIZE-Outcomes studies – part of AZ’s CRYSTALIZE programme for the drug – have been shelved because patients were being enrolled into them more slowly than hoped for, and clinical events were occurring at a lower rate than expected.

Patients 79

Patients 79

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

Pharmaceutical Technology

DECEMBER 1, 2023

Biocon subsidiary Biocon Biologics has successfully integrated Viatris' biosimilars business in 31 countries in Europe.

98

98

MedCity News

DECEMBER 1, 2023

Opposing sides are girding for a likely momentous constitutional confrontation.

114

114

Pharmaceutical Technology

DECEMBER 1, 2023

Partnership deals involving psychedelic drugs saw a 500% growth in total deal volume from 2019 to 2023 year-to-date (YTD).

98

98

PharmaTimes

DECEMBER 1, 2023

Every year, around 55,000 women in the UK are diagnosed with the condition - News - PharmaTimes

Patients 102

Patients 102

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

PharmExec

DECEMBER 1, 2023

How to build a loyal audience of brand evangelists.

Media 115

Media Healthcare Healthcare 115

MedCity News

DECEMBER 1, 2023

NODE.Health 7th annual conference. December 6-8, 2023, Microsoft NYC, New York.

Medicine 94

Medicine 94

PharmExec

DECEMBER 1, 2023

The FDA previously granted accelerated approval to the Keytruda plus Padcev combination for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

FDA 59

FDA Patients 59

pharmaphorum

DECEMBER 1, 2023

FDA starts review of Padcev/Keytruda for bladder cancer Phil.

FDA 95

FDA 95

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management